Menu
Česky English Deutsch
+420 532 23 1111

Průtoková cytometrie - publikace

Vybrané publikace

[1]  R. Greil, P. Obrtlíková, L. Smolej, T. Kozák, M. Steurer, J. Andel, S. Burgstaller, E. Mikušková, L. Gercheva, T. Nösslinger, T. Papajík, M. Ladická, M. Girschikofsky, M. Hrubiško, U. Jäger, M. Fridrik, M. Pecherstorfer, E. Králiková, C. Burcoveanu, E. Spasov, A. Petzer, G. Mihaylov, J. Raynov, H. Oexle, A. Zabernigg, E. Flochová, S. Palášthy, O. Stehlíková, M. Doubek, P. Altenhofer, L. Pleyer, T. Melchardt, A. Klingler, J. Mayer, and A. Egle, “Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial,” Lancet Haematol, vol. 3, no. 7, pp. e317-329, Jul. 2016.

[2]  A. C. Rawstron, C. Fazi, A. Agathangelidis, N. Villamor, R. Letestu, J. Nomdedeu, C. Palacio, O. Stehlikova, K.-A. Kreuzer, S. Liptrot, D. O’Brien, R. M. de Tute, I. Marinov, M. Hauwel, M. Spacek, J. Dobber, A. P. Kater, P. Gambell, A. Soosapilla, G. Lozanski, G. Brachtl, K. Lin, J. Boysen, C. Hanson, J. L. Jorgensen, M. Stetler-Stevenson, C. Yuan, H. E. Broome, L. Rassenti, F. Craig, J. Delgado, C. Moreno, F. Bosch, A. Egle, M. Doubek, S. Pospisilova, S. Mulligan, D. Westerman, C. M. Sanders, R. Emerson, H. S. Robins, I. Kirsch, T. Shanafelt, A. Pettitt, T. J. Kipps, W. G. Wierda, F. Cymbalista, M. Hallek, P. Hillmen, E. Montserrat, and P. Ghia, “A complementary role of multiparameter flow-cytometry and high-throughput sequencing for minimal residual disease (MRD) detection in chronic lymphocytic leukemia (CLL): An european research initiative on CLL (ERIC) study,” Leukemia, Dec. 2015.

[3]  J. Chovancová, T. Bernard, O. Stehlíková, D. Šálek, A. Janíková, J. Mayer, and M. Doubek, “Detection of minimal residual disease in mantle cell lymphoma-establishment of novel eight-color flow cytometry approach,” Cytometry B Clin Cytom, vol. 88, no. 2, pp. 92–100, Mar. 2015.

[4]  M. Doubek, Y. Brychtova, A. Panovska, L. Sebejova, O. Stehlikova, J. Chovancova, J. Malcikova, J. Smardova, K. Plevova, P. Volfova, M. Trbusek, M. Mraz, D. Bakesova, J. Trizuljak, M. Hadrabova, P. Obrtlikova, J. Karban, L. Smolej, A. Oltova, E. Jelinkova, S. Pospisilova, and J. Mayer, “Ofatumumab added to dexamethasone in patients with relapsed or refractory chronic lymphocytic leukemia: Results from a phase II study,” Am. J. Hematol., vol. 90, no. 5, pp. 417–421, May 2015.

[5]  O. Stehlíková, J. Chovancová, B. Tichý, M. Krejčí, Y. Brychtová, A. Panovská, H. Francová Skuhrová, K. Burčková, M. Borský, T. Loja, J. Mayer, S. Pospíšilová, and M. Doubek, “Detecting minimal residual disease in patients with chronic lymphocytic leukemia using 8-color flow cytometry protocol in routine hematological practice,” Int J Lab Hematol, vol. 36, no. 2, pp. 165–171, Apr. 2014.

Informace o pohotovosti v Brně a Jihomoravském kraji